好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Secretory Products of B Cells Are Cytotoxic to Oligodendroglia [italic]In Vitro[/italic]
MS and Related Diseases
(-)
006
Authors/Disclosures
Robert P. Lisak, MD, FAAN (Wayne State Univ Sch of Med, Dept of Neuro) Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argnex. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Bridge Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alivar Therapeutics. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ANI Pharmaceuticals. Dr. Lisak has received personal compensation in the range of $0-$499 for serving as a Consultant for Coleman Research. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunic. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tedus Consulting. Dr. Lisak has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for COUR Pharma. The institution of Dr. Lisak has received research support from NINDS. The institution of Dr. Lisak has received research support from Argenx. The institution of Dr. Lisak has received research support from Ra Pharmaceuticals. Dr. Lisak has received publishing royalties from a publication relating to health care. Dr. Lisak has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Trina Johnson, MD No disclosure on file
Sathyanath Rajasekharan, PhD (McGill Experimental Therapeutics Program) No disclosure on file
No disclosure on file
Amit Bar-Or, MD, FRCPC (University of Pennsylvania) Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merk/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving as a Consultant for cabaletta. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/EMD Serono. Dr. Bar-Or has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. The institution of Dr. Bar-Or has received research support from Novartis. The institution of Dr. Bar-Or has received research support from Biogen. The institution of Dr. Bar-Or has received research support from Roche/Genentech.